Study directory

Depression studies

Compare studies and check their requirements with the research team.

6115studies shown

Showing 1,777-1,788 of 6,115

CompletedEUCTR 2009-014045-92

Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder. An 8-week randomis...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Czech Republic

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: France, Czechia, Estonia, ...
Sponsor: Institut de Recherches Internationales Servier
Condition: Depression

View study

CompletedEUCTR 2015-003867-13

Efficacy and safety of S 47445 versus placebo as adjunctive treatment of Major Depressive Disorder in patients with an inadequate response to antidepressant therapy. A randomised, double-blind, pla...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Bulgaria, Czechia, Finland, ...
Sponsor: Institut de Recherches internationales Servier
Condition: Depression

View study

CompletedEUCTR 2012-005612-26

Efficacy and safety of tianeptine oral administration (25 to 50 mg/day) in elderly patients suffering from Major Depressive Disorder. A 8-week, randomized, double-blind, flexible-dose, parallel gr...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Bulgaria, Estonia, Finland, ...
Sponsor: Institut de Recherches Internationales Servier
Condition: Depression

View study

CompletedEUCTR 2012-004062-17

Efficacy of add-on pregabalin in the treatment of Generalized Anxiety Disorder comorbid with Major Depressive Disorder: a double-blind placebo-controlled study.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Greece

Why is this study shown?

This study is directly about Depression.

Depression, AnxietyDrug

Countries: Greece
Sponsor: Aristotle University of Thessaloniki
Condition: Depression, Anxiety

View study

CompletedEUCTR 2004-004009-10

Efficacy of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally on rest/activity circadian rhythms in outpatients with Major Depressive Disorder. A randomized, double-blind inte...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Austria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Austria, Germany, Italy, ...
Sponsor: Institut de Recherches Internationales Servier [...] 1. Institut de Recherches Internationales Servier 2. Laboratorios Servier S.L. (For Spain only)
Condition: Depression

View study

CompletedEUCTR 2006-006540-54

Efficacy of agomelatine (25 to 50 mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder. A randomised, double-blind, flexible-dose international multice...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: France, United Kingdom
Sponsor: Institut de Recherches Internationales Servier
Condition: Depression

View study

TerminatedEUCTR 2021-005007-12

Efficacy of Trazodone Once-a-Day for treatment of Major Depressive Disorder in patients with breast cancer.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Bulgaria
Sponsor: Angelini Pharma S.p.A.
Condition: Depression

View study

CompletedEUCTR 2006-003658-47

Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In France

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: France
Sponsor: Pierre Fabre Médicament - IRPF
Condition: Depression

View study

CompletedEUCTR 2014-003547-35

Interventional, open-label, flexible-dose, long-term study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in elderly patients with major depressive disorder with a...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Estonia

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Estonia, Finland, Germany, ...
Sponsor: H. Lundbeck A/S
Condition: Depression

View study

TerminatedEUCTR 2012-004169-42

Interventional, open-label, long-term extension study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in patients with major depressive disorder.

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Bulgaria

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: United Kingdom, Bulgaria, Estonia, ...
Sponsor: H. Lundbeck A/S
Condition: Depression

View study

CompletedEUCTR 2010-024632-42

LY2216684 compared to Placebo as Adjunctive Therapy to SSRI in the Prevention of Symptom Re-emergence in Major Depressive Disorder

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Belgium, Germany, Greece, ...
Sponsor: Eli Lilly and Company
Condition: Depression

View study

CompletedEUCTR 2020-004291-18

Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In Belgium

Why is this study shown?

This study is directly about Depression.

DepressionDrug

Countries: Belgium, Bulgaria, Czechia, ...
Sponsor: Janssen-Cilag International NV
Condition: Depression

View study

Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.